AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA

AEON Biopharma, Inc.

Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.
Daewoong exchanged $15M senior secured notes for 11.9M shares, 11.2M pre-funded warrants, $1.5M new note, and 8M warrants.
Second closing of PIPE expected week of Jan 26: 4.6M shares, 6.6M warrants, and up to 6.6M true-up warrants.
AEON held BPD Type 2a meeting with FDA for ABP-450 biosimilar; awaiting official minutes within ~30 days.
Fifth amendment to license agreement with Daewoong adjusts termination purchase right based on Daewoong's sale of 50% of its shares.

item 3.02 item 5.02 item 5.07 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.